Form 4: Enanta Pharmaceuticals Chief Business Officer Sells Shares to Cover Tax Obligations

Enanta Pharmaceuticals' Chief Business Officer, Brendan Luu, sold 2,283 shares of common stock to cover tax obligations related to a restricted stock unit award.

Summary

• Brendan Luu, Chief Business Officer of Enanta Pharmaceuticals, sold 2,283 shares of common stock on December 6, 2024.
• The sale was executed to cover withholding taxes due from the settlement of a restricted stock unit award granted on November 23, 2022.
• The shares were sold at a weighted-average price of $8.06, with individual transactions ranging from $7.87 to $8.22.
• Following the transaction, Mr. Luu beneficially owns 36,047 shares of Enanta Pharmaceuticals stock.

Sentiment

Score: 5

Explanation: The document reflects a routine transaction for tax purposes, not indicative of any positive or negative sentiment regarding the company's performance or future prospects.

Management Comments

• The sale was to satisfy tax withholding obligations to be funded by a 'sell to cover' transaction and does not represent a discretionary transaction by the reporting person.

Industry Context

This is a routine transaction for executives who receive stock-based compensation. It is common for executives to sell shares to cover tax obligations when restricted stock units vest.

Comparison to Industry Standards

• Similar transactions are common across the pharmaceutical industry and other sectors where stock-based compensation is a significant part of executive pay.
• Many companies use 'sell to cover' mechanisms to manage tax obligations for employees receiving stock awards.
• The sale of 2,283 shares is not unusual for an executive at this level.

Stakeholder Impact

• The transaction has a minimal impact on shareholders as it is a routine sale to cover tax obligations.

Key Dates

Keywords

Enanta Pharmaceuticals, Brendan Luu, stock sale, insider trading, Form 4, restricted stock unit, tax obligations